Elagox 200 mg (Tablet)
Unit Price: ৳ 220.00 (1 x 10: ৳ 2,200.00)
Strip Price: ৳ 2,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Elagolix sodium |
| Company | Nuvista pharma ltd |
| Also available as |
Indications
- Management of moderate to severe pain associated with endometriosis
Pharmacology
- GnRH receptor antagonist
- Inhibits endogenous GnRH signaling
- Competitively binds to GnRH receptors in the pituitary gland
- Suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Decreases blood concentrations of estradiol and progesterone
Dosage & Administration
- Initial treatment with Elagolix 150 mg
- Initial treatment with Elagolix 200 mg
- Dosage recommendation based on hepatic impairment
- Usage in children and adolescents
Interactions
- Potential interaction with P-gp substrates and CYP2C19 substrates
- Antagonistic interaction with CYP3A substrates, oral midazolam, and rosuvastatin
- Reduced efficacy with estrogen-containing contraceptives
Contraindications
- Contraindicated in pregnant women
- Contraindicated with known osteoporosis
- Contraindicated in severe hepatic impairment
- Contraindicated with concomitant use of strong organic anion transporting polypeptide OATP1B1 inhibitors
Side Effects
- Common side effects include hot flushes, night sweats, headache, nausea, amenorrhea, arthralgia, mood changes, and bone loss
- Rare side effects include insomnia, anxiety, and elevated hepatic transaminase
Pregnancy & Lactation
- Insufficient human data for use in pregnant women
- Increased risk of early pregnancy loss
- Contraindicated during pregnancy
- Discontinue if pregnancy occurs during treatment
- No information on presence in human milk or effects on breastfed child
Precautions & Warnings
- Dose and duration-dependent decreases in bone mineral density (BMD)
- Reduced ability to recognize pregnancy
- Potential for suicidal ideation and mood disorders
- Dose-dependent elevations in serum alanine aminotransferase (ALT)
- Potential for reduced efficacy with estrogen-containing contraceptives
Use in Special Populations
- No dose adjustment required in women with renal impairment or end-stage renal disease
- No dose adjustment required in women with mild hepatic impairment
- Safety and effectiveness not established in patients less than 18 years of age
Overdose Effects
- Monitoring for signs or symptoms of adverse reactions
- Initiating appropriate symptomatic treatment
Therapeutic Class
- Gonadotropin-releasing hormone (GnRH) antagonist
Storage Conditions
- Store in a cool & dry place
- Protect from light & moisture
- Keep out of reach of children